학술논문
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
Document Type
Article
Author
Source
In European Urology Focus November 2022 8(6):1696-1702
Subject
Language
ISSN
2405-4569